Aptinyx Inc (NASDAQ:APTX) Could Burn Your Long Portfolio After More Shorts

October 2, 2018 - By Clifton Ray

The stock of Aptinyx Inc (NASDAQ:APTX) registered an increase of 5.96% in short interest. APTX’s total short interest was 335,900 shares in October as published by FINRA. Its up 5.96% from 317,000 shares, reported previously. With 47,400 shares average volume, it will take short sellers 7 days to cover their APTX’s short positions. The short interest to Aptinyx Inc’s float is 2.49%.

The stock decreased 0.80% or $0.23 during the last trading session, reaching $28.48. About 58,629 shares traded. Aptinyx Inc. (NASDAQ:APTX) has 0.00% since October 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company has market cap of $953.97 million. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. It currently has negative earnings. The firm has a collaboration agreement with Allergan plc.

More news for Aptinyx Inc. (NASDAQ:APTX) were recently published by: Nasdaq.com, which released: “Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the …” on September 14, 2018. Globenewswire.com‘s article titled: “Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference” and published on September 25, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>